Its values, its interview process and the questions it asks, in short episodes. Listen on a walk, then practice.
10 episodes1 free to try
No subscription needed
The Lilly an employee experiences day-to-day is shaped by two things glossy materials don't capture well: the Catalyze360 external-innovation arm (Lilly Ventures, Gateway Labs, ExploR&D, TuneLab) that connects Lilly to the broader biotech ecosystem, and the deep ERG and inclusion infrastructure inside the company. This module gives you the cultural texture so when interviewers ask "What kind of environment do you work best in?" or "What questions do you have for us?" you can have a substantive conversation about what working at Lilly actually feels like.
Lilly's success story has hard edges. The 2024 Mounjaro/Zepbound supply shortage left patients without medicines. Lilly is in active legal battles with compounding pharmacies. The Trump-administration "Most Favored Nation" pricing deal in September 2025 cut prices 85% for Medicaid/Medicare. None of this gets discussed in glossy investor presentations, but a smart interviewer may probe how you think about these topics — because integrity, ethics, and access are central to Lilly's identity. This module gives you balanced, factual framings so you can engage maturely without overcommitting to a partisan view.
Multiple Glassdoor reports describe Lilly's interview process as "entirely based on STAR responses." Two interviewers per panel, each asking 4-6 behavioral questions, alternating turns. Each round is roughly 30 minutes. This module gives you the precise process map — recruiter screen, hiring manager round, two panels, optional technical screen — plus the specific behavioral questions candidates report being asked, and the STAR delivery mechanics that prevent your answer from being downscored.
Since 2020 Lilly has committed more than $50 billion to U.S. manufacturing — the largest such investment by any pharmaceutical company in U.S. history. Lebanon, Indiana is now a $9 billion site for tirzepatide API. The Lilly Medicine Foundry adds $4.5 billion for advanced manufacturing and clinical-trial production. In February 2025 Lilly announced four additional new sites. This module walks you through the manufacturing footprint, why it matters, and how to talk about it whether you're interviewing for an operations, engineering, quality, supply chain, or commercial role.
Lilly is being publicly described in CIO and life-sciences press as one of the first true "AI-native" enterprises in pharma. CIDO Diogo Rau came from Apple in 2021 and has built a stack that includes the LillyPod (an NVIDIA DGX SuperPOD with 1,016 Blackwell GPUs), the TuneLab platform (which gives biotech partners free access to Lilly's AI/ML drug-discovery models), and Magnol.AI for digital biomarkers. This module helps anyone interviewing into a tech, data, digital, or AI role — or any role that touches digital — understand what's actually being built and how to talk about it.
Hiring managers at Lilly often complain that candidates only know the GLP-1 story and miss the much broader pipeline. Kisunla (donanemab) was Lilly's first-ever Alzheimer's medicine, approved in July 2024, and is reshaping early-disease neurology. Verzenio is delivering 7-year survival data in early breast cancer. Imlunestrant, olomorasib, and Jaypirca are deepening the oncology bench. This module gives you the non-GLP-1 portfolio fluency that signals to interviewers you actually understand the company.
Lilly's GLP-1 franchise is the most consequential commercial story in pharma in a generation. Mounjaro and Zepbound have driven Lilly to roughly 60% of the U.S. obesity/diabetes market. The April 2026 FDA approval of Foundayo (orforglipron), a daily oral GLP-1 pill, is widening the moat. And retatrutide is a Phase 3 triple-agonist that has produced 29% body-weight loss at 68 weeks. This module gives you the science, the competitive dynamics, and the strategic narrative — so when you say "I'm excited about the GLP-1 work," you actually know what you're talking about.
David Ricks took over as Lilly's CEO in January 2017 with a market cap around $70 billion. By September 2025 it had touched $700 billion — a 10x in less than nine years, making Lilly the most valuable pharma company in history. This module decodes the strategy behind that run so you can talk about Lilly's direction with substance: the bet on incretins and Alzheimer's, the productivity reset of R&D, and the patient-first philosophy Ricks has anchored every decision to.
Lilly's three core values—Integrity, Excellence, and Respect for People—are the rubric your interview answers will be scored against, whether or not the panelists explicitly say so. They have guided the company since founding, and Lilly's own materials use the phrase "Team Lilly" to describe the cultural expectation: collaborative, creative, engaged. This module decodes what each value means in practice, which kinds of stories land for each, and which red flags to avoid.
Eli Lilly was founded in Indianapolis in 1876 by a 38-year-old Civil War veteran and pharmacist who promised to make medicines "of the highest possible quality" that would be "prescribed by physicians" and "based on the best scientific knowledge." That promise is still the company's identity 150 years later. This module gives you the deep heritage story so you can answer "Why Lilly?" with substance — pulling on the through-line from insulin in 1923 to Mounjaro in 2022 — instead of platitudes.